Racing the anchor leg of the biathlon mixed relay 4x6km, Julia Simon led France to victory at the Olympic Winter Games Milano Cortina 2026 on Sunday, 8 February.
Simon raced home to Antholz-Anterselva Biathlon Stadium in a time of…

Racing the anchor leg of the biathlon mixed relay 4x6km, Julia Simon led France to victory at the Olympic Winter Games Milano Cortina 2026 on Sunday, 8 February.
Simon raced home to Antholz-Anterselva Biathlon Stadium in a time of…

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Extremely Profitable Stocks to Invest in Now.
Pixabay/Public Domain
On February 2, 2026, Reuters reported that long-standing expectations that the global obesity drug market would reach $150 billion over the next decade are being reconsidered amid declining U.S. prices for GLP-1 therapies and intensifying competition. The new projections indicate that the market will reach closer to $100 billion by 2030, which is roughly 30% less than previous estimates. Furthermore, the $150 billion mark is not expected to be reached until 2035.
Citing pressure from cash-pay competition and faster-than-expected generic entry, Jefferies reduced its peak market estimate by 20% in January. The firm’s expected market size as of 2035 stands at $80 billion.
Even with these revised assumptions, LSEG’s consensus estimates still expect Eli Lilly and Company (NYSE:LLY) to deliver more than 21% revenue growth and more than 40% adjusted earnings growth in 2026 compared to 2025.
Against this backdrop of demand, Lilly outlined its strategic initiative two days earlier.
On January 30, 2026, Eli Lilly and Company (NYSE:LLY) announced that it would construct a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, which will be its fourth new location in the United States. As GLP-1 competition accelerates, the plant will work on injectable weight-loss drug production like retatrutide, with construction expected to begin this year and operations starting in 2031.
Eli Lilly and Company (NYSE: LLY) develops and commercializes innovative medicines across diabetes, obesity, oncology, immunology, and neuroscience.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: What Are the Best Stocks to Buy Right Now? and 10 Stocks Under $1 That Will Explode.
Disclosure: None.
You don’t have permission to access “http://www.olympics.com/en/milano-cortina-2026/news/winter-olympics-2026-why-milano-cortina-is-the-ultimate-goodbye-for-franziska-preuss/” on this server.
Reference…

LONDON — British Prime Minister Keir Starmer’s chief of staff resigned Sunday over the furor surrounding the appointment of Peter Mandelson as the U.K. ambassador to the U.S. despite his ties to Jeffrey Epstein.
Morgan McSweeney said he took…

For the world’s smallest sea turtles, life in the ocean is getting pretty noisy. These relatively little turtles (on average they’re still 75 to 100 pounds) mostly found in the Gulf of Mexico already face fishing gear accidents, seacraft…
A woman has blamed Mounjaro for her ‘excruciating pain’ as she faces gallbladder removal surgery after using the weight loss drug.
In an article for The Telegraph, Catherine Hales from the UK opened up about how she had struggled with her weight…

Developers looking to gain a better understanding of machine learning inference on local hardware can fire up a new llama engine.
Software developer Leonardo Russo has released llama3pure, which incorporates three standalone inference engines….
You don’t have permission to access “http://www.olympics.com/en/milano-cortina-2026/news/winter-olympics-2026-how-to-watch-team-usa-live-full-schedule-and-medal-events-on-monday-9-february/” on this server.
Reference…